BEVERLY, Mass.--(BUSINESS WIRE)--March 1, 2006--Cell Signaling Technology, Inc. (CST) announced today that it has been issued a second U.S. Patent (No. 6,982,318) covering a novel and powerful class of motif-specific and context-independent antibodies, and has received a notice of allowance in a third U.S. application directed to the same technology. CST's patent portfolio covers antibodies that are capable of binding modified motifs, such as phosphorylated kinase consensus motifs and protein-protein binding motifs, as well as a method for producing them. These antibodies are useful for profiling protein modification, and can be used to identify signaling pathways in cells and to study alterations of these pathways in disease.
